<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1625">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04357327</url>
  </required_header>
  <id_info>
    <org_study_id>68/2020</org_study_id>
    <nct_id>NCT04357327</nct_id>
  </id_info>
  <brief_title>Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19)</brief_title>
  <official_title>Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19): a Diagnostic Accuracy Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Università degli Studi dell'Insubria</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Università degli Studi dell'Insubria</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present Diagnostic Accuracy study aims at experimentally validating the use of a rapid
      salivary test to detect SARS-CoV-2 infection in both symptomatic and asymptomatic individuals
      as a preliminary approach to a mass screening program.

      The study is based on a consecutive recruitment of both patients showing symptoms probably
      associated with COVID-19 (i.e., cough, dyspnea, fever) and asymptomatic patients with a low
      risk phenotype. The expected number of recruited individuals is 100.

      The experimental test is a prototype of salivary test based on the Lateral Flow Immunoassay
      technique and is able to detect the presence of SARS-CoV-2 in saliva, especially the Spike
      protein (S). The comparison is represented by the nasopharyngeal swab, the gold standard of
      COVID-19 diagnosis.

      Patients will undergo both salivary immunoassay and nasopharyngeal swab, thus the outcome
      assessors are blinded, since the results of the rRT-PCR analysis require at least 6 hours
      before being available.

      The main outcomes are sensibility and specificity of the rapid salivary test, when compared
      with the gold standard (nasopharyngeal swab).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 16, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Consecutive recruitment of both patients with COVID-19 like symptoms (i.e., cough, fever, dyspnea) and patients with low risk phenotype</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The rapid salivary test will provide results within 5-10 minutes, while the rRT-PCR performed on nasopharyngeal swab shows results only after 6 hours, thus the outcome assessor of the experimental test is blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Sensibility</measure>
    <time_frame>Salivary test will be interpreted after 10 minutes; the nasopharyngeal swab after 6 hours; sensitivity recorded through study completion, an average of 2 months.</time_frame>
    <description>TP/TP+FN (TP= True Positive; FN = False Negative)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity</measure>
    <time_frame>Salivary test will be interpreted after 10 minutes; the nasopharyngeal swab after 6 hours; specificity recorded through study completion, an average of 2 months.</time_frame>
    <description>TN/TN+FP (TN= True Negative; FP= False Positive)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID-19</condition>
  <condition>SARS-CoV 2</condition>
  <condition>Corona Virus Infection</condition>
  <arm_group>
    <arm_group_label>Symptomatic patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with symptoms associated with COVID-19, i.e., dyspnea, cough, fever, etc.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asymptomatic subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Asymptomatic patients with low risk phenotype, that means patients with a previous negative swab, no relatives affected by COVID-19 and with reduced social interaction within the last two weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>rapid salivary test</intervention_name>
    <description>a rapid salivary test to detect SARS-CoV-2 spike protein in saliva with a lateral flow immunoassay</description>
    <arm_group_label>Asymptomatic subjects</arm_group_label>
    <arm_group_label>Symptomatic patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        People who undergo nasopharyngeal swab to confirm or exclude SARS-CoV-2 infection

        Exclusion Criteria:

        none
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lorenzo Azzi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Università degli Studi dell'Insubria</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lorenzo Azzi</last_name>
    <phone>+393476766856</phone>
    <email>l.azzi@uninsubria.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>ASST dei Sette Laghi</name>
      <address>
        <city>Varese</city>
        <state>VA</state>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorenzo Azzi, DDS</last_name>
      <phone>+39-3476766856</phone>
      <email>l.azzi@uninsubria.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 15, 2020</study_first_submitted>
  <study_first_submitted_qc>April 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2020</study_first_posted>
  <last_update_submitted>April 22, 2020</last_update_submitted>
  <last_update_submitted_qc>April 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Università degli Studi dell'Insubria</investigator_affiliation>
    <investigator_full_name>Lorenzo Azzi</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Saliva</keyword>
  <keyword>nCoV-2019</keyword>
  <keyword>Coronavirus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We could provide anamnestic, clinical and serological data of each participant at the end of the study, or at least at the end of the first phase.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data will be available at the end of the study, once statistical analyses is conducted</ipd_time_frame>
    <ipd_access_criteria>Contact Principal Investigator</ipd_access_criteria>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Scientific paper</doc_type>
      <doc_url>https://www.sciencedirect.com/science/article/pii/S0163445320302139</doc_url>
      <doc_comment>Recently, we published a study that demonstrates that saliva is a promising diagnostic tool to detect SARS-CoV-2. We analyzed salivary samples of 25 patients affected by COVID-19 and all of them proved positive at rRT-PCR analysis.</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

